← Eichor
Study identifier: NCT05169229 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement.

Condition: Arthroplasty, Replacement, Hip · Osteoarthritis, Hip · Antibiotic Resistant Infection  ·  Sponsor: University Hospital, Linkoeping

PhasePhase 2
Planned participants1100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Total hip replacement is the most successful treatment modern healthcare can offer patients to regain quality of life. Periprosthetic joint infection (PJI) is the most common and devastating complication after total hip replacement (THR). Between 0.5 to 2% of primary THR (first time hip replacement), and 8-10% of revision THR (replacement of a hip prosthesis) will become infected.1 The introduction of local antibiotics blended into bone cement has led to a reduction in postoperative infection in primary THR by half.2 Unfortunately, cement can't always be used in relevant quantities. The number of primary and revision surgeries of the hip is projected to increase dramatically. Therefore, the need for a feasible infection prophylaxis that is applicable for complex primary and revision THR in addition to antibiotics loaded cement is urgent. Impacted morselized bone allograft is often used in (revision) THR to fill bone defects. Morselized allograft has been used as a carrier for local antibiotic treatment in multiple pilot studies and appears to be an attractive and effective treatment option, both for already infected joints and as a prophylactic measure in high-risk patients (e.g. THR revision surgeries). Nonetheless, a pivotal trial to support its use in THR is lacking. The aim of this pragmatic randomized controlled double blinded drug trial is to investigate whether antibiotic impregnated bone graft (AIBG) decreases the risk of infection after hip arthroplasty compared to…

This description comes directly from the study's public registry record.

Talk to the study team

Daphne Wezenberg, PhD  ·  0046101030000  ·  daphne.wezenberg@liu.se

Always discuss trial participation with your own doctor first.

Locations (1)

Universitetssjukhuset LinköpingLinköping, Region Östergotland, SwedenRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05169229